On November 30, 2022, H.C. Wainwright & Co., LLC hosted the First Annual Bacteriophage Conference to highlight what H.C. Wainwright & Co. believes to be a major pending inflection point in the field. Intralytix was one of the phage companies featured at the conference, with our President and CEO, Dr. Alexander "Sandro" Sulakvelidze presenting. Here is a copy of the summary about Intralytix as provided by H.C. Wainwright & Co (with permission, courtesy of H.C. Wainwright & Co., LLC):
"Intralytix revs up its engines with an extensive list of assets and proprietary technologies PhageSelector and PhageEngine. In the last private company presentation, Dr. Alexander "Sandro" Sulakvelidze, president and CEO of Intralytix, provided an overview of his company and its goal to control bacterial pathogens in environmental, food processing, and medical settings. Intralytix is a platform-based company developing phage products for various applications, including food safety,
Dr. Alexander "Sandro" Sulakvelidze, President & CEO of Intralytix. prevention and/or treatment of human diseases, dietary supplements/probiotics/drugs for fine-tuning the microbiome, and animal health applications. It is the first company worldwide to receive FDA approval for phage products relating to food safety applications; five food safety products are currently FDA approved and three of those five approved in Israel and Canada. Further, Intralytix has three INDs approved, which includes one in a phase 1/2a clinical trial underway at Mt. Sinai Medical Center focusing on adhesive invasive E. coli in Crohn’s disease. The two others were approved by the FDA for phase 1/2a studies in Shigella and vancomycin resistant enterococci, which plan to start early 2023. With a nice, broad overview of distinct phage applications and products, we feel that Intralytix is poised to potentially branch off these different applications and products into new businesses, potential spin-off companies, or as novel divisions of the company. We next want to highlight two significant advances discussed during the presentation: (1) PhageSelector and (2) PhageEngine. PhageSelector is a proprietary program developed by Intralytix that organizes panels of phage efficacy data and generates a rank-ordered list of phages to combine into an optimal phage cocktail for a given target. The program provides a deeper understanding into phage-host pair interactions through a high throughput robotics system. PhageEngine is an AI-based platform developed by Intralytix that can provide insights into phage needed to kill a specific bacterial strain as well as a framework for optimal phage-host growth dynamics. The program demonstrates rapid classification and scalability of phage products. Lastly, we want to highlight that Intralytix is revenue generating, which represents a major milestone within a space where such a situation had yet to come to fruition. It attributes company revenue to sales, partnership agreements with industry partners, and grant funding. We believe that Intralytix will continue its success in the coming years due to the significant milestones achieved thus far and as the bacteriophage space grows in recognition and popularity."
H.C. Wainwright & Co., LLC is one of the country's oldest and most trusted financial institutions. The
Company offers investment banking, advisory, research, sales, and trading services.